U.S. Industrials Stock News

Vaxart (VXRT) is drawing fresh attention ahead of its scheduled presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. Investors will be listening for pipeline and funding updates. See our latest analysis for Vaxart. Vaxart’s recent 34.83% 7 day share price return and 102.97% 90 day share price return point to building momentum ahead of the conference, even as the 5 year total shareholder return of 87.31% highlights longer term challenges. If...

PicS N.V. completed a US$434.3 million initial public offering. The company began trading on the Nasdaq Global Select Market under the ticker NasdaqGS:PICS. This is the first new stock listing by a Brazilian company in over four years. With its IPO now complete, PicS enters the public markets at a share price of $17.76 and a recent 7 day return of 17.6%. The listing of NasdaqGS:PICS also marks a return of Brazilian issuers to international equity markets after a multi year pause in new...

International General Insurance Holdings (IGIC) has put income front and center by declaring an extraordinary cash dividend of $1.15 per share, payable on April 6, 2026, to shareholders of record on March 18. See our latest analysis for International General Insurance Holdings. The extraordinary and ordinary dividends, along with the recently completed US$8.09 million buyback, come after a period where the share price has moved steadily rather than sharply. The 30 day share price return is...

Terns Pharmaceuticals (TERN) has drawn attention after recent trading, with the stock closing at US$40.92. For investors, the clinical stage focus on oncology and obesity raises questions about how current pricing reflects trial progress and cash needs. See our latest analysis for Terns Pharmaceuticals. While the share price slipped around 1% on the day to US$40.92, it remains on a strong short term run, with a 16.61% 1 month share price return and a 45.57% 3 month share price return,...

National Storage Affiliates Trust (NYSE:NSA) reported solid Q4 operational progress, including better occupancy metrics and revenue trends across most markets. The company completed the consolidation of another brand, aiming to simplify its platform and improve operational consistency. NSA continued to refine its portfolio through asset sales, new acquisitions and joint ventures, while keeping liquidity conditions supportive of these moves. For investors tracking NYSE:NSA, the recent...

Churchill Downs (CHDN) has wrapped up FY 2025 with fourth quarter revenue of US$665.9 million and basic EPS of US$0.71, alongside trailing twelve month revenue of US$2.9 billion and EPS of US$5.36. The company has seen quarterly revenue move from US$624.2 million in Q4 2024 to US$665.9 million in Q4 2025, while basic EPS shifted from US$0.99 to US$0.71 over the same period. This sets up a contrast with a trailing net margin of 13.1% versus 15.6% a year earlier, which keeps investor attention...

If you are wondering whether J&J Snack Foods is starting to look attractively priced, you are not alone. This article will help you make sense of where the stock stands today. The shares last closed at US$85.11, with returns of 0.0% over 7 days, a 9.7% decline over 30 days, a 6.0% decline year to date, and a 33.6% decline over 1 year that sits against a 36.5% decline over 3 years and a 39.4% decline over 5 years. These moves have kept J&J Snack Foods on the radar for investors looking at...

Nu Holdings (NYSE:NU) has capped FY 2025 with fourth quarter revenue of US$2.1b and basic EPS of US$0.18, while trailing twelve month revenue sits at US$7.0b with EPS of US$0.59, underscoring a period where earnings grew 45.5% over the past year and are forecast to grow about 26.4% per year over the next three years. Over recent periods, the company has seen revenue move from US$5.5b and EPS of US$0.41 on a trailing basis in Q4 2024 to US$7.0b and EPS of US$0.59 by Q4 2025, alongside a...

Disc Medicine (NasdaqGM:IRON) received a Complete Response Letter from the FDA for its bitopertin candidate for erythropoietic protoporphyria, shifting the drug to a traditional approval pathway. The company now plans to rely on its ongoing APOLLO Phase III trial as the core data package for future regulatory submissions. Management expects APOLLO to reach full enrollment soon, making the trial a key focus for the bitopertin program. For you as an investor, this update centers on how Disc...

If you are wondering whether Rigetti Computing's recent share price puts it above or below a reasonable value, you are not alone. This article is designed to help you frame that question clearly. Rigetti's stock closed at US$18.64, with a 17.1% return over the past week, a 15.3% decline over the past month, a 21.0% decline year to date, and a 120.3% return over the past year. These moves may leave you questioning whether the current price reflects opportunity or higher risk. Recent news...

Sterling Infrastructure (STRL) has wrapped up FY 2025 with fourth quarter revenue of US$755.6 million and basic EPS of US$2.85, alongside net income of US$87.6 million, setting a clear marker for how the year finished. Over the past six quarters, the company has seen quarterly revenue move from US$498.8 million in Q4 2024 to US$755.6 million in Q4 2025, while basic EPS shifted from US$3.69 to US$2.85 and trailing twelve month EPS went from US$5.98 in Q3 2024 to US$9.50 in Q4 2025, giving...

Perfect Corp. recently announced a partnership with True Beauty Lashes to power LashLovr™, an AI-driven lash matching and virtual try-on experience that uses its Virtual Try-On and Face Analyzer APIs to help shoppers find better-fitting false lashes in real time. This collaboration highlights how Perfect’s pay-as-you-go AI and AR APIs can lower adoption hurdles for beauty brands while showcasing a concrete, research-backed use case that could support broader B2B uptake of its technology...

How OneStream (OS) Has Been Trading Recently With no single headline event driving OneStream (OS) today, investors are instead weighing its recent share performance, revenue profile, and current losses to assess how the stock fits into their software exposure. See our latest analysis for OneStream. At a recent share price of $23.60, OneStream sits on a 90 day share price return of 13.3% and a year to date share price return of 33.18%, while the 1 year total shareholder return is 3.1%. This...

The Morning Bull - US Market Morning Update Friday, Feb, 27 2026 US stock futures are pointing slightly lower this morning, with E-mini S&P 500 futures down about 0.2%, as investors weigh cheaper borrowing costs against mixed global growth signals. The 30 year US mortgage rate has dipped below 6% to 5.98%, which can make monthly payments a bit less painful and puts housing related names in focus. At the same time, the Kansas Fed Manufacturing Index has bounced to 10, a sign that factory...

Ducommun (DCO) has wrapped up FY 2025 with fourth quarter revenue of US$215.8 million and basic EPS of US$0.50, alongside net income of US$7.4 million. The trailing twelve month figures show revenue of US$824.7 million and a net loss of US$33.9 million tied to basic EPS of US$2.27. Over recent quarters, revenue has moved from US$197.3 million in Q4 2024 to US$215.8 million in Q4 2025, with quarterly basic EPS ranging from a loss of US$4.30 in Q3 2025 to a profit of US$0.50 in Q4 2025. For...

Are you wondering if Global Industrial still offers good value after its recent run, or if the current price already reflects the key positives for the business? The stock last closed at US$33.26, with returns of 4.3% over 7 days, 9.9% over 30 days, 13.1% year to date, 48.4% over 1 year, 32.6% over 3 years and 10.4% over 5 years. This naturally raises questions about what is now priced in. Recent coverage has focused on Global Industrial's role as a distributor of industrial and business...

Axsome Therapeutics (NasdaqGM: AXSM) has started the CLARITY Phase 3 trial of solriamfetol in major depressive disorder with excessive daytime sleepiness. The trial focuses on a group of MDD patients who experience excessive daytime sleepiness, for which no approved treatments are currently available. This study expands Axsome's clinical program into an area of unmet medical need. Axsome Therapeutics, listed on the NasdaqGM under the ticker AXSM, develops therapies for central nervous...

SPX Technologies is pursuing an acquisition-led expansion and investing heavily in capacity, including in data center infrastructure. The company recently reported record earnings that align with this repositioning of its business mix. At the same time, insider selling and shifts in institutional ownership are reshaping who holds NYSE:SPXC shares. For investors, this mix of corporate activity and ownership changes makes NYSE:SPXC a stock to watch. The shares recently closed at $231.59, with...

Ultragenyx Pharmaceutical (NasdaqGS:RARE) announced that the US FDA has accepted its Biologics License Application for DTX401, a gene therapy for Glycogen Storage Disease Type Ia. The FDA has granted Priority Review to the application, signaling an expedited assessment timeline. If approved, DTX401 could become the first pharmacologic treatment option for people living with Glycogen Storage Disease Type Ia. For Ultragenyx, with a current share price of $23.04, this regulatory milestone...

IDEXX Laboratories (NasdaqGS:IDXX) announced the upcoming retirement of long-serving Board member M. Anne Szostak. The company also disclosed the appointment of Michael G. Erickson, PhD, to its Board of Directors. These Board changes reflect an ongoing refresh of corporate governance and Board composition. IDEXX Laboratories focuses on diagnostic and software solutions for veterinary practices, livestock, poultry, and water testing, placing the company at the center of long term trends in...

In February 2026, Aspen Aerogels reported fourth-quarter 2025 sales of US$41.34 million versus US$123.09 million a year earlier, swung to a net loss of US$72.91 million, recorded an impairment charge on property, plant and equipment, and launched a broad review of options for its business and capital structure. An important insight is that management characterizes this strategic review as coming from a position of financial strength and operational progress, even as the company posts a...

Central Securities Corporation (NYSE American: CET) has released its annual report for the year ended December 31, 2025, reporting full-year net income of US$265.21 million. The annual report gives investors a clearer view into how this closed-end investment company managed its portfolio and operations over the 2025 calendar year. We will now examine how Central Securities’ 2025 net income performance shapes the company’s investment narrative for shareholders and prospective...

Nvidia (NVDA) has put up big headline numbers for FY 2026, with fourth quarter revenue of about US$68.1b and basic EPS of US$1.77, capping a year in which trailing 12 month EPS reached US$4.93 alongside revenue of roughly US$215.9b. Over the past six quarters, the company has seen quarterly revenue move from about US$35.1b with EPS of US$0.79 in FY 2025 Q3 to US$68.1b and EPS of US$1.77 in FY 2026 Q4. This sets up a story where investors are watching how rich margins and strong earnings...

Wondering whether Plug Power's share price around US$1.91 is starting to look like value, or if it still carries more risk than upside? You are not alone in asking that question right now. The stock has been flat over the last 7 days, while the 30 day return is a 20.7% decline, set against a 17.2% gain over 1 year and much weaker 3 and 5 year returns of 85.7% and 95.2% declines. Recent news flow has focused on Plug Power's position in hydrogen and fuel cell markets, as investors weigh long...